News|Articles|November 18, 2026

Q3 Healthcare Report Cites Federal Research Cuts and FDA Staff Losses as Pressures on Biotech

Listen
0:00 / 0:00

Key Takeaways

  • NIH research and training dollars function as a core upstream asset-creation and workforce “farm club,” and constraints on grants, renewals, and visas threaten future staffing and capacity.
  • Major FDA headcount reductions at CDER and CBER, plus senior departures, are associated with disruptions to development timelines, approval processes, and potential downstream safety risks.
SHOW MORE

Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.

“We’ve seen sites turning more towards industry sponsored trials to drive more revenue and ultimately cover some of the research they’re doing that was NIH and other government funded research.”

Investment bank Cassel Salpeter & Co. cites federal funding cuts, staffing losses at the FDA, and tariffs as pressures on the US biotech industry in its Q3 2026 healthcare update. In a section titled “Is the Government Strangling Biotech?”, the report looks at how government policy affects drug development and the companies behind it.1

The National Institutes of Health (NIH) is central to the report’s discussion of government’s role. It describes the NIH as the government’s most important contribution to the biotech ecosystem and says the agency has funded “almost $200 billion in laboratory and clinical research” since 2021. That research has produced technologies and molecules that became the basis for new companies or were licensed or sold to biotech firms.

Pressure on grants and training

The report states that the administration continues to push for control of and cuts to research spending. Congress has resisted some of those demands, it says, but some cuts have been made. Grant processing has also been disrupted, including new applications and renewals of grants and contracts, which adds pressure on research and training programs.

Clinical research infrastructure is part of that picture. The report notes that National Cancer Institute (NCI)-designated cancer centers train oncologists and clinical scientists and host clinical trials, and that NIH money supports graduate and postdoctoral training programs, which it describes as “farm clubs” for the industry. Cuts to training grants and fewer visas for foreign workers may make it harder to staff new US facilities.

FDA losses and a tougher financing climate

At the FDA, the report says the agency has lost more than 3,500 employees since January 20, 2025, including 800 from the Center for Drug Evaluation and Research (CDER) and almost 400 from the Center for Biologics Evaluation and Research (CBER). Almost 1,000 additional staffers resigned or took early retirement, including senior scientists and administrators. The report states that the cuts have caused major disruptions to drug development and approval and may affect the safety of the nation’s drug supply.

Tariffs add cost and uncertainty. The report says they will disproportionately affect small and mid-sized biotechs, and that even early-stage labs will face higher costs for imported materials. Uncertainty over tariffs is keeping investors “on the sidelines when it comes to early-stage companies,” and IPOs from more mature companies are fewer than last year and not performing well. Combined with slower federal grants and higher operating costs, the report describes fundraising as extremely difficult.

How sites were already adapting

Research sites were feeling the funding squeeze well before this report. In a 2025 video interview with Applied Clinical Trials, Kyle McAllister, co-founder and CEO of Trially, described how sites and sponsors were responding to clinical trial budget cuts. They were “doing more with less,” he said, turning to telemedicine, remote monitoring tools, and teams that had not previously worked together across multiple types of studies or departments.

Sites were also leaning more on industry-sponsored trials. “We’ve seen sites turning more towards industry sponsored trials to drive more revenue and ultimately cover some of the research they’re doing that was NIH and other government funded research, essentially using pharma money to keep the lights on and keep things moving forward,” McAllister said.

He saw a trade-off. A shift toward more industry-sponsored research, he said, means institutional priorities moving away from public interest-focused research. Some sites were also cutting staff and closing departments and research programs, and the research capacity lost with them would take time to grow back. “Sites are doing heroic work out there, but I worry that heroism isn’t a sustainable staffing model,” McAllister said.

References
  1. Q3 2026 Healthcare Report: Is the Government Strangling Biotech? Cassel Salpeter & Co. https://www.casselsalpeter.com/general/q3-2026-healthcare-report/
  2. How Sites and Sponsors Are Adapting to Clinical Trial Budget Cuts. Applied Clinical Trials. July 1, 2025. https://www.appliedclinicaltrialsonline.com/view/sites-sponsors-adapting-clinical-trial-budget-cuts


Related to this article